Skip to main content

Jaguar Health, Inc.

corporate_fare Company Profile

Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed JAGX - Latest Insights

JAGX
Apr 27, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
8
JAGX
Apr 27, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
JAGX
Apr 21, 2026, 8:22 AM EDT
Filing Type: PRE 14A
Importance Score:
10
JAGX
Apr 21, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
JAGX
Apr 13, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
JAGX
Apr 09, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
9
JAGX
Apr 08, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
JAGX
Apr 07, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
9
JAGX
Apr 07, 2026, 6:10 AM EDT
Filing Type: 10-K
Importance Score:
9
JAGX
Mar 24, 2026, 5:06 PM EDT
Filing Type: DEF 14A
Importance Score:
9
JAGX
Mar 16, 2026, 9:00 AM EDT
Source: Acceswire
Importance Score:
7
JAGX
Mar 13, 2026, 4:59 PM EDT
Filing Type: PRE 14A
Importance Score:
9
JAGX
Mar 09, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
9
JAGX
Mar 09, 2026, 9:00 AM EDT
Source: Acceswire
Importance Score:
9
JAGX
Mar 06, 2026, 4:23 PM EST
Source: Wiseek News
Importance Score:
9
JAGX
Mar 06, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
9
JAGX
Mar 03, 2026, 9:05 AM EST
Filing Type: 8-K
Importance Score:
9
JAGX
Mar 03, 2026, 9:00 AM EST
Source: Acceswire
Importance Score:
9
JAGX
Feb 18, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
9
JAGX
Jan 23, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
9